1,6-二(P-乙酰氧基羰基苯氧基)己烷 | 151078-50-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,6-二(P-乙酰氧基羰基苯氧基)己烷
• 中文别名: 1,6-双(对乙酰氧羰基苯氧基)己烷
• 英文名称: 1,6-Bis(p-acetoxycarbonylphenoxy)hexane
• 英文别名: acetyl 4-[6-(4-acetyloxycarbonylphenoxy)hexoxy]benzoate
• CAS: 151078-50-1
• 化学式: C₂₄H₂₆O₈
• 分子量: 442.5
• InChiKey: UPRXYEYFWUUHHL-UHFFFAOYSA-N

物化性质

• 沸点：
  622.5±55.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi,N
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

文献信息

• Telomerase delivery by biodegradable Nanoparticle
  申请人：Lin Xin

  公开号：US20090142408A1

  公开（公告）日：2009-06-04

  A therapeutic compound consisting of human telomerase, its catalytic subunit hTert, or a known variant of either, and a biodegradable nanoparticle carrier, which can be administered to cells in a cell culture or in a living animal, is provided herein. The therapeutic compound is envisioned as a method for treating a wide variety of age-related diseases such as idiopathic pulmonary fibrosis, aplastic anemia, dyskeratosis congenita, arteriosclerosis, macular degeneration, osteoporosis, Alzheimer's, diabetes type 2, and any disease that correlates with telomere shortening and may be corrected or ameliorated by lengthening telomeres. The therapeutic compound is also envisioned as method for potentially treating more generic problems of human aging. The nanoparticle carrier is comprised of certain biodegradable biocompatible polymers such as poly(lactide-co-glycolide), poly(lactic acid), poly(alkylene glycol), polybutylcyanoacrylate, poly(methylmethacrylate-co-methacrylic acid), poly-allylamine, polyanhydride, polyhydroxybutyric acid, polycaprolactone, lactide-caprolactone copolymers, polyhydroxybutyrate, polyalkylcyanoacrylates, polyanhydrides, polyorthoester or a combination thereof. The nanoparticle may incorporate a targeting moiety to direct the nanoparticle to a particular tissue type or a location within a cell. The nanoparticle may incorporate a plasticizer to facilitate sustained release of telomerase such as L-tartaric acid dimethyl ester, triethyl citrate, or glyceryl triacetate. A nanoparticle of the present invention can further contain a polymer that affects the charge or lipophilicity or hydrophilicity of the particle. Any biocompatible hydrophilic polymer can be used for this purpose, including but not limited to, poly(vinyl alcohol).
• FUNCTIONALIZED MOLECULES COMPRISING AN AUTOSILIFICATION MOIETY AND METHODS OF MAKING AND USING SAME
  申请人：Marner, II Wesley D.

  公开号：US20100173367A1

  公开（公告）日：2010-07-08

  The present invention provides functionalized molecules comprising a covalently linked autosilification moiety; and methods for making and using the functionalized molecules. The present invention provides nucleic acids comprising nucleotide sequence encoding polypeptides comprising an autosilification moiety. The present invention further provides silica matrices comprising a subject functionalized molecule, as well as systems and kits comprising the silica matrices. The subject functionalized molecules find use in various applications, which are also provided.
• ANTIPARASITIC POLYANHYDRIDE NANOPARTICLES
  申请人：Iowa State University Research Foundation, Inc.

  公开号：US20150216888A1

  公开（公告）日：2015-08-06

  Filarial parasites Brugia, Wuchereria, Loa Loa and Onchocerca cause over 20 million infections worldwide and pose a significant social and economic burden in endemic areas. The invention provides compositions and methods to treat parasitic infections in animals and plants, and to kill and inhibit the replication of parasites in infected hosts. The methods can include administering to a host in need of treatment an effective antiparasitic amount of a composition comprising biodegradable polyanhydride microparticles or nanoparticles that encapsulate antiparasitic agents, optionally in combination with antibacterial agents. Through co-encapsulation of antiparasitic and antibacterial agents into the particles, the invention provides the ability to effectively kill parasitic helminthes, worms, and flukes, with up to a 40-fold reduction in the amount of drug used. The results described herein demonstrate the effectiveness of the drug carriers to reduce both the course of treatment and the amount of drug needed to treat parasitic infections.
• US7659322B1
  申请人：——

  公开号：US7659322B1

  公开（公告）日：2010-02-09
• US8449916B1
  申请人：——

  公开号：US8449916B1

  公开（公告）日：2013-05-28